Image 1 of 1
Cartalax is a short synthetic peptide bioregulator (Ala-Glu-Asp-Pro) designed to support the regeneration of cartilage and connective tissue. Research indicates it helps stimulate chondrocyte activity, enhance extracellular matrix synthesis, and may protect against cartilage degeneration in osteoarthritic or injury-related conditions.
Scientific Overview
Cartalax belongs to the cytomedin class of bioregulatory peptides, originally developed in Russia for organ-specific cellular regeneration. Derived from cartilage tissue, it is formulated to act as a signaling molecule that restores the function of chondrocytes—the cells responsible for cartilage health and repair.
Studies suggest that Cartalax modulates gene expression and protein synthesis related to collagen type II, proteoglycan, and hyaluronic acid production, contributing to improved joint integrity and elasticity.
Mechanism of Action
Cartalax is believed to work through:
• Epigenetic modulation of RNA transcription, promoting cellular differentiation in cartilage tissue.
• Activation of regenerative signaling (via TGF-β and IGF pathways).
• Protection against oxidative stress, reducing inflammatory cytokines and preventing apoptosis in chondrocytes.
• Normalization of local metabolism, supporting cartilage matrix restoration after injury or degeneration.
Potential Benefits
• Supports cartilage repair and joint mobility
• May reduce pain and inflammation associated with osteoarthritis
• Promotes elasticity and lubrication within connective tissues
• Aids recovery from joint surgeries or sports injuries
• Enhances long-term tissue resilience under load or repetitive strain
Research Applications
• Studies in degenerative joint disease and osteoarthritis
• Experimental use in cartilage graft regeneration
• Investigation into post-trauma recovery and tissue remodeling
• Adjunct to chondroprotective therapies (e.g., BPC-157, TB-500, GHK-Cu)
Reconstitution & Storage
• Reconstitution: Add 2 mL of sterile bacteriostatic water per 10 mg vial for research purposes.
• Storage (Lyophilized): Store in a cool, dry place below 25°C, away from light.
• Storage (Reconstituted): Refrigerate at 2–8°C. Use within 28 days.
Research Notes
Cartalax shows synergy when combined with BPC-157 and TB-500, forming a comprehensive repair triad:
• Cartalax – targets cartilage
• BPC-157/TB-500 – target tendon, ligament, and muscleThis multi-tissue approach may enhance total recovery outcomes and long-term joint integrity.
Dosage: if used as a standalone, 1-2 mg per day for 30 days straight.
Can be used as part of a cartilage and joint restoration stack by dosing the following daily for 4-8 weeks:
1 mg Cartalax
500 mcg BPC-157
500 mcg TB-500
205 mg GHK-cu
Cartalax is available at TuraWellness.com